Tempest Therapeutics (NASDAQ:TPST) Releases Earnings Results, Meets Estimates

Tempest Therapeutics (NASDAQ:TPST) issued its earnings results on Monday. The company reported ($0.62) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.62), FiscalAI reports.

Tempest Therapeutics Price Performance

Shares of TPST stock opened at $1.73 on Monday. The firm has a market cap of $8.52 million, a price-to-earnings ratio of -0.17 and a beta of -2.42. Tempest Therapeutics has a 12 month low of $1.56 and a 12 month high of $12.23. The stock has a 50-day moving average price of $2.37 and a 200 day moving average price of $5.27.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tempest Therapeutics in a report on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $12.50.

Insider Transactions at Tempest Therapeutics

In other Tempest Therapeutics news, CEO Matthew Angel bought 231,482 shares of the stock in a transaction on Tuesday, March 24th. The stock was purchased at an average price of $2.16 per share, with a total value of $500,001.12. Following the acquisition, the chief executive officer owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.28% of the company’s stock.

Institutional Investors Weigh In On Tempest Therapeutics

An institutional investor recently bought a new position in Tempest Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 11,444 shares of the company’s stock, valued at approximately $33,000. Dimensional Fund Advisors LP owned 0.23% of Tempest Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.